BioMarin Pharmaceuticals Inc (BMRN)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 3,221
- Market Cap
- $11.7B
About BioMarin Pharmaceuticals Inc
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
SentiSense also tracks daily options readings for BioMarin Pharmaceuticals Inc: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
BioMarin Pharmaceuticals Inc stock analysis, sentiment tracking, and market intelligence on SentiSense.